---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010282"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:00:34.763332+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lixte Biotechnology relieved of $3.1M funding obligation for Phase 2 sarcoma study

## Summary
- Amendment No. 1 to clinical trial agreement with GEIS relieves Lixte of approx $3,095,000 obligation for randomized Phase 2 portion.
- Phase 1b recruitment completed in Q3 2024; initial toxicity and preliminary efficacy data expected Q4 2025.
- Study overall expected to be completed and report prepared by Dec 31, 2026.
- Lixte's lead compound LB-100 studied with doxorubicin for advanced soft tissue sarcomas.

## SEC filing metadata
- accession: 0001493152-25-010282
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315225010282/0001493152-25-010282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315225010282/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010282
- JSON: https://secwatch.observer/filing/0001493152-25-010282.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.